Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Methylglyoxal (MGO) is a reactive dicarbonyl compound and a potential key player in diabetic cardiovascular disease (CVD). Whether plasma MGO levels are associated with CVD in type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS: We included 1,003 individuals (mean ± SD age 59.1 ± 10.5 years, 69.3% male, and 61.6% with prior CVD) with type 2 diabetes from the Second Manifestations of ARTerial disease cohort (SMART). We measured plasma MGO levels and two other dicarbonyls (glyoxal [GO] and 3-deoxyglucosone [3-DG]) at baseline with mass spectrometry. Median follow-up of CVD events was 8.6 years. Data were analyzed with Cox regression with adjustment for sex, age, smoking, systolic blood pressure, total cholesterol, HbA1c, BMI, prior CVD, and medication use. Hazard ratios are expressed per SD Ln-transformed dicarbonyl. RESULTS: A total of 287 individuals suffered from at least one CVD event (n = 194 fatal events, n = 146 myocardial infarctions, and n = 72 strokes); 346 individuals died, and 60 individuals underwent an amputation. Higher MGO levels were associated with total (hazard ratio 1.26 [95% CI 1.11–1.42]) and fatal (1.49 [1.30–1.71]) CVD and with all-cause mortality (1.25 [1.11–1.40]), myocardial infarction (1.22 [1.02–1.45]), and amputations (1.36 [1.05–1.76]). MGO levels were not apparently associated with stroke (1.03 [0.79–1.35]). Higher GO levels were significantly associated with fatal CVD (1.17 [1.00–1.37]) but not with other outcomes. 3-DG was not significantly associated with any of the outcomes. CONCLUSIONS: Plasma MGO and GO levels are associated with cardiovascular mortality in individuals with type 2 diabetes. Influencing dicaronyl levels may therefore be a target to reduce CVD in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389 · cited 2×
“Thismay help close the persistent gap in cardiovascular mortality between individuals with and without diabetes (1).”
BackgroundEl-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., & Brownlee, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081188 · Cited by 1,115 · cited 9×
“We therefore may have underestimated the mediating effect of LGI on the associations between dicarbonyls and CVD outcomes.”
BackgroundInfluentialAndersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248
Integrative Genomics Reveals Novel Molecular Pathways and Gene Networks for Coronary Artery Disease
Mäkinen, V.-P., Civelek, M., Meng, Q., Zhang, B., Zhu, J., Levian, C., Huan, T., Segrè, A. V., Ghosh, S., Vivar, J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004502 · Cited by 196
Koska, J., Saremi, A., Howell, S., Bahn, G., De Courten, B., Ginsberg, H., Beisswenger, P. J., Reaven, P. D., & for the VADT Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1740 · Cited by 134 · cited 1×
“A recent report has investigated associations between several dicarbonyl-derived AGEs and incident CVD in participants with type 2 diabetes (19), and the overall associations between these MGO-derived AGEs and incident CVD seemed to attenuate largely after adjustment for prior CVD and other confounders, while in our r…”
Background
Cited by
van Sloten, T. T., Sedaghat, S., Carnethon, M. R., Launer, L. J., & Stehouwer, C. D. A. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30405-x · Cited by 702
Self-citationReactive oxygen species (ROS) in macrophage activation and function in diabetes
Rendra, E., Riabov, V., Mossel, D. M., Sevastyanova, T., Harmsen, M. C., & Kzhyshkowska, J. (2019) · Immunobiology · doi:10.1016/j.imbio.2018.11.010 · Cited by 636
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Self-citationPostprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
Self-citation
Metadata
- Authors
- Hanssen, N. M. J., Westerink, J., Scheijen, J. L. J. M., van der Graaf, Y., Stehouwer, C. D. A., Schalkwijk, C. G., SMART Study Group, Algra, A., van der Graaf, Y., Grobbee, R. D. E., Rutten, G. E. H. M., Visseren, F. L. J., de Borst, G. J., Kappelle, J. L. J., Leiner, T., & Nathoe, H. M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-05-21
- Volume
- 41
- Issue
- 8
- Pages
- 1689-1695
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2804992601
- Cited by
- 103
- References
- 6
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.